A failure at Eli Lilly, the comeback drug teplizumab shows off more upbeat diabetes data in the run-up to an FDA filing
Provention Bio has some more positive data to add to its looming BLA for a new treatment designed to delay the onset of diabetes among …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
